Last $10.65 USD
Change Today +1.70 / 18.99%
Volume 1.0M
LJPC On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

la jolla pharmaceutical co (LJPC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $19.50
52 Week Low
07/26/13 - $2.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

la jolla pharmaceutical co (LJPC) Related Bloomberg News

View More Bloomberg News

la jolla pharmaceutical co (LJPC) Related Businessweek News

No Related Businessweek News Found

la jolla pharmaceutical co (LJPC) Details

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company’s products include GCS-100 that is in Phase II clinical trial for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome; and LJPC-401, a peptide for the treatment of iron disorders. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

7 Employees
Last Reported Date: 03/31/14
Founded in 1989

la jolla pharmaceutical co (LJPC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $420.0K
Compensation as of Fiscal Year 2013.

la jolla pharmaceutical co (LJPC) Key Developments

La Jolla Pharmaceutical Co. - Special Call

To discuss the plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension

La Jolla Pharmaceutical Co. Announces Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension

La Jolla Pharmaceutical Co. announced that the company plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH), a new indication. Initiation of this registration program is the result of a recent meeting between the Company and the U.S. Food and Drug Administration at which agreement was reached that blood pressure is an appropriate primary endpoint for approval. Hypotension, if uncorrected, is life-threatening and occurs as the result of various underlying conditions such as blood loss due to trauma, septic shock, poor heart function or drug reactions. The first line of treatment is catecholamine infusion. Catecholamines are derived from the amino acid tyrosine and include epinephrine (adrenaline), norepinephrine (noradrenaline), and dopamine, which act as neurotransmitters that increase blood pressure. While largely effective, some patients fail to respond to adequate doses and are defined as catecholamine-resistant. Furthermore, high doses of catecholamines can lead to cardiac and other toxicities, and can contribute to the high rate of mortality in these patients. Therefore, there is a major unmet need for a new pharmacological agent that can restore blood pressure while maintaining catecholamine doses at acceptable levels. LJPC-501 (angiotensin II) is a peptide agonist of the renin-angiotensin system that acts to stabilize blood pressure. One of the most widely prescribed classes of blood pressure medication, angiotensin converting enzyme inhibitors, inhibits the production of angiotensin II, thereby reducing blood pressure. A randomized, placebo-controlled pilot study of angiotensin II in 20 patients with catecholamine-resistant hypotension was presented at the 34(th) International Symposium on Intensive Care and Emergency Medicine by Dr. Lakhmir S. Chawla from George Washington University. This study demonstrated that the mean norepinephrine dose for the placebo cohort was 20.1 +/- 16.8 g/minute vs. 7.3 +/- 11.9 g/minute for the angiotensin II cohort (P = 0.022). This was the pre-defined primary endpoint and a surrogate measure of blood pressure effect. Approximately 80% of patients treated with angiotensin II experienced a rise in blood pressure compared to 10-20% with placebo. The most common adverse event was hypertension, which occurred in 20% of patients receiving angiotensin II. Due to the estimated size of the patient population in the United States for this indication, the Company has filed for Orphan Drug status for angiotensin II.

La Jolla Pharmaceutical Company Appoints Robert H. Rosen as Board of Directors

La Jolla Pharmaceutical Company announced the appointment of Robert H. Rosen to the company's Board of Directors. Robert H. Rosen is currently President and a Director of Heron Therapeutics. He joined the company in October 2012 as Sr. Vice President and Chief Commercial Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $10.65 USD +1.70

LJPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJPC.
View Industry Companies

Industry Analysis


Industry Average

Valuation LJPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at